Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e.
Intranasal delivery of vaccines directed against respiratory pathogens is an attractive alternative to parenteral administration. However, using this delivery route for inactivated vaccines usually requires the use of potent mucosal adjuvants, and no such adjuvant has yet been approved for human use...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3602086?pdf=render |
| _version_ | 1811320767514673152 |
|---|---|
| author | Hana Kammoun Xavier Roux Dominique Raze Anne-Sophie Debrie Marina De Filette Tine Ysenbaert Nathalie Mielcarek Xavier Saelens Walter Fiers Camille Locht |
| author_facet | Hana Kammoun Xavier Roux Dominique Raze Anne-Sophie Debrie Marina De Filette Tine Ysenbaert Nathalie Mielcarek Xavier Saelens Walter Fiers Camille Locht |
| author_sort | Hana Kammoun |
| collection | DOAJ |
| description | Intranasal delivery of vaccines directed against respiratory pathogens is an attractive alternative to parenteral administration. However, using this delivery route for inactivated vaccines usually requires the use of potent mucosal adjuvants, and no such adjuvant has yet been approved for human use.We have developed a live attenuated Bordetella pertussis vaccine, called BPZE1, and show here that it can be used to present the universal influenza virus epitope M2e to the mouse respiratory tract to prime for protective immunity against viral challenge. Three copies of M2e were genetically fused to the N-terminal domain of filamentous hemagglutinin (FHA) and produced in recombinant BPZE1 derivatives in the presence or absence of endogenous full-length FHA. Only in the absence of FHA intranasal administration of the recombinant BPZE1 derivative induced antibody responses to M2e and effectively primed BALB/c mice for protection against influenza virus-induced mortality and reduced the viral load after challenge. Strong M2e-specific antibody responses and protection were observed after a single nasal administration with the recombinant BPZE1 derivative, followed by a single administration of M2e linked to a virus-like particle without adjuvant, whereas priming alone with the vaccine strain did not protect.Using recombinant FHA-3M2e-producing BPZE1 derivatives for priming and the universal influenza M2e peptide linked to virus-like particles for boosting may constitute a promising approach for needle-free and adjuvant-free nasal vaccination against influenza. |
| first_indexed | 2024-04-13T13:05:11Z |
| format | Article |
| id | doaj.art-76fea82cec6f481fa0101ed8df745b73 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T13:05:11Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-76fea82cec6f481fa0101ed8df745b732022-12-22T02:45:47ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0183e5919810.1371/journal.pone.0059198Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e.Hana KammounXavier RouxDominique RazeAnne-Sophie DebrieMarina De FiletteTine YsenbaertNathalie MielcarekXavier SaelensWalter FiersCamille LochtIntranasal delivery of vaccines directed against respiratory pathogens is an attractive alternative to parenteral administration. However, using this delivery route for inactivated vaccines usually requires the use of potent mucosal adjuvants, and no such adjuvant has yet been approved for human use.We have developed a live attenuated Bordetella pertussis vaccine, called BPZE1, and show here that it can be used to present the universal influenza virus epitope M2e to the mouse respiratory tract to prime for protective immunity against viral challenge. Three copies of M2e were genetically fused to the N-terminal domain of filamentous hemagglutinin (FHA) and produced in recombinant BPZE1 derivatives in the presence or absence of endogenous full-length FHA. Only in the absence of FHA intranasal administration of the recombinant BPZE1 derivative induced antibody responses to M2e and effectively primed BALB/c mice for protection against influenza virus-induced mortality and reduced the viral load after challenge. Strong M2e-specific antibody responses and protection were observed after a single nasal administration with the recombinant BPZE1 derivative, followed by a single administration of M2e linked to a virus-like particle without adjuvant, whereas priming alone with the vaccine strain did not protect.Using recombinant FHA-3M2e-producing BPZE1 derivatives for priming and the universal influenza M2e peptide linked to virus-like particles for boosting may constitute a promising approach for needle-free and adjuvant-free nasal vaccination against influenza.http://europepmc.org/articles/PMC3602086?pdf=render |
| spellingShingle | Hana Kammoun Xavier Roux Dominique Raze Anne-Sophie Debrie Marina De Filette Tine Ysenbaert Nathalie Mielcarek Xavier Saelens Walter Fiers Camille Locht Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e. PLoS ONE |
| title | Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e. |
| title_full | Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e. |
| title_fullStr | Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e. |
| title_full_unstemmed | Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e. |
| title_short | Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e. |
| title_sort | immunogenicity of live attenuated b pertussis bpze1 producing the universal influenza vaccine candidate m2e |
| url | http://europepmc.org/articles/PMC3602086?pdf=render |
| work_keys_str_mv | AT hanakammoun immunogenicityofliveattenuatedbpertussisbpze1producingtheuniversalinfluenzavaccinecandidatem2e AT xavierroux immunogenicityofliveattenuatedbpertussisbpze1producingtheuniversalinfluenzavaccinecandidatem2e AT dominiqueraze immunogenicityofliveattenuatedbpertussisbpze1producingtheuniversalinfluenzavaccinecandidatem2e AT annesophiedebrie immunogenicityofliveattenuatedbpertussisbpze1producingtheuniversalinfluenzavaccinecandidatem2e AT marinadefilette immunogenicityofliveattenuatedbpertussisbpze1producingtheuniversalinfluenzavaccinecandidatem2e AT tineysenbaert immunogenicityofliveattenuatedbpertussisbpze1producingtheuniversalinfluenzavaccinecandidatem2e AT nathaliemielcarek immunogenicityofliveattenuatedbpertussisbpze1producingtheuniversalinfluenzavaccinecandidatem2e AT xaviersaelens immunogenicityofliveattenuatedbpertussisbpze1producingtheuniversalinfluenzavaccinecandidatem2e AT walterfiers immunogenicityofliveattenuatedbpertussisbpze1producingtheuniversalinfluenzavaccinecandidatem2e AT camillelocht immunogenicityofliveattenuatedbpertussisbpze1producingtheuniversalinfluenzavaccinecandidatem2e |